JP2024527629A5 - - Google Patents
Info
- Publication number
- JP2024527629A5 JP2024527629A5 JP2024503765A JP2024503765A JP2024527629A5 JP 2024527629 A5 JP2024527629 A5 JP 2024527629A5 JP 2024503765 A JP2024503765 A JP 2024503765A JP 2024503765 A JP2024503765 A JP 2024503765A JP 2024527629 A5 JP2024527629 A5 JP 2024527629A5
- Authority
- JP
- Japan
- Prior art keywords
- mutain
- optionally
- polypeptide
- fusion protein
- iii
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB2110547.3A GB202110547D0 (en) | 2021-07-22 | 2021-07-22 | Therapeutic muteins |
| GB2110547.3 | 2021-07-22 | ||
| FR2203600 | 2022-04-19 | ||
| FR2203600 | 2022-04-19 | ||
| PCT/EP2022/070548 WO2023001987A2 (en) | 2021-07-22 | 2022-07-21 | Therapeutic muteins |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024527629A JP2024527629A (ja) | 2024-07-25 |
| JP2024527629A5 true JP2024527629A5 (https=) | 2025-07-28 |
Family
ID=82942857
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024503765A Pending JP2024527629A (ja) | 2021-07-22 | 2022-07-21 | 治療用ムテイン |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20240352084A1 (https=) |
| EP (1) | EP4373848A2 (https=) |
| JP (1) | JP2024527629A (https=) |
| CA (1) | CA3226397A1 (https=) |
| IL (1) | IL310292A (https=) |
| WO (1) | WO2023001987A2 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023249425A1 (ko) * | 2022-06-22 | 2023-12-28 | ㈜지아이이노베이션 | 항-cd73 항체 및 il-2를 포함하는 융합단백질 및 이의 용도 |
| AU2024330564A1 (en) | 2023-08-30 | 2026-04-02 | Xilio Development, Inc. | Vhh masked cytokines and methods of use thereof |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7569215B2 (en) * | 2003-07-18 | 2009-08-04 | Massachusetts Institute Of Technology | Mutant interleukin-2 (IL-2) polypeptides |
| GB201403775D0 (en) | 2014-03-04 | 2014-04-16 | Kymab Ltd | Antibodies, uses & methods |
| CA3007135A1 (en) | 2016-03-23 | 2017-09-28 | Mabspace Biosciences (Suzhou) Co., Ltd | Novel anti-pd-l1 antibodies |
| MX2018014950A (es) | 2016-06-07 | 2019-04-25 | Macrogenics Inc | Terapia de combinacion. |
| WO2018045110A1 (en) | 2016-08-30 | 2018-03-08 | Xencor, Inc. | Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors |
| EP3534947A1 (en) | 2016-11-03 | 2019-09-11 | Kymab Limited | Antibodies, combinations comprising antibodies, biomarkers, uses & methods |
| PE20250933A1 (es) | 2017-03-14 | 2025-04-02 | Five Prime Therapeutics Inc | Anticuerpos de union a vista a ph acido |
| US20180339043A1 (en) | 2017-05-26 | 2018-11-29 | Janux Therapeutics, Inc. | Modified antibodies |
| US12202911B2 (en) | 2017-10-10 | 2025-01-21 | Numab Therapeutics AG | Multispecific antibody comprising CD137 binding domain and PDL1 binding domain |
| IL275426B2 (en) * | 2017-12-19 | 2025-03-01 | Xencor Inc | Engineered il-2 fc fusion proteins |
| WO2019152413A1 (en) | 2018-02-02 | 2019-08-08 | Oncoimmune, Inc. | Methods of selecting and designing safer and more effective anti-ctla-4 antibodies for cancer therapy |
| BR112020019083A2 (pt) | 2018-03-21 | 2020-12-29 | Five Prime Therapeutics, Inc. | Anticorpos, ácido nucleico, composições, célula e métodos para preparar um anticorpo, para tratar câncer, para tratar uma doença infecciosa, para tratar uma inflamação, para a identificação de um anticorpo, para melhorar a eficácia antitumoral de um anticorpo, para melhorar a farmacocinética de um anticorpo, para selecionar um anticorpo, para melhorar a eficácia de anticorpos, para isolar anticorpos, para detectar vista em uma amostra e para tratar câncer |
| US10597453B2 (en) | 2018-06-29 | 2020-03-24 | Gensun Biopharma, Inc. | Antitumor immune checkpoint regulator antagonists |
| US20220002370A1 (en) | 2018-09-27 | 2022-01-06 | Xilio Development, Inc. | Masked cytokine polypeptides |
| CN119874917A (zh) | 2019-06-07 | 2025-04-25 | 阿迪马布有限责任公司 | 工程化的pH依赖性抗CD3抗体及其产生和使用方法 |
| KR102560876B1 (ko) | 2019-06-11 | 2023-07-28 | 바이오아트라, 인코퍼레이티드 | 조건부 활성 항-epcam 항체, 항체 단편, 이들의 면역접합체 및 이의 용도 |
| PH12022550326A1 (en) | 2019-08-13 | 2023-03-13 | Amgen Inc | Interleukin-2 muteins for the expansion of t-regulatory cells |
-
2022
- 2022-07-21 EP EP22757224.5A patent/EP4373848A2/en active Pending
- 2022-07-21 WO PCT/EP2022/070548 patent/WO2023001987A2/en not_active Ceased
- 2022-07-21 CA CA3226397A patent/CA3226397A1/en active Pending
- 2022-07-21 US US18/290,928 patent/US20240352084A1/en active Pending
- 2022-07-21 JP JP2024503765A patent/JP2024527629A/ja active Pending
- 2022-07-21 IL IL310292A patent/IL310292A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US12275769B2 (en) | Activatable interleukin 12 polypeptides and methods of use thereof | |
| ES3021463T3 (en) | Dll3/cd3 binding proteins for cancer treatment | |
| CN113248624B (zh) | Syntac多肽及其用途 | |
| CN103180339B (zh) | 具有改善的稳定性的基于纤连蛋白的支架蛋白质 | |
| CN113286609B (zh) | 多聚体t细胞调节多肽及其使用方法 | |
| US10428149B2 (en) | Single-chain tumor necrosis factor (TNF) ligand family molecules, fusion proteins and derivatives thereof | |
| CN110582297B (zh) | 包含T细胞接合抗体构建体的低pH药物组合物 | |
| CN113301919A (zh) | 激活免疫细胞的双特异性抗体 | |
| CN118852460A (zh) | 具有非FcγR依赖性激动活性的肿瘤坏死因子(TNF)受体超家族(TNFRSF)受体-激活抗体融合蛋白(具有非FcγR依赖性激动活性的TNFRSF受体-激活抗体融合蛋白；TRAAFFIAA) | |
| JP2022512043A5 (https=) | ||
| RS61399B1 (sr) | Vezne belančevine slične antitelu sa dva varijabilna regiona koje imaju ukrštenu orijentaciju veznog regiona | |
| JP2024527629A5 (https=) | ||
| JP2023525495A (ja) | 抗ｃｄ２６タンパク質及びそれらの使用法 | |
| JP2024524922A5 (https=) | ||
| ES3036457T3 (en) | A cd33-, cd16- and cd123-specific single chain triplebody | |
| TW202128758A (zh) | 多專一性融合蛋白及其用途 | |
| WO2020132135A1 (en) | Multimeric t-cell modulatory polypeptides and methods of use thereof | |
| GB2566389B (en) | Antigen binding molecules that bind light | |
| CN104292331A (zh) | 人源抗人α干扰素抗体及其应用 | |
| WO2016112497A1 (zh) | 人源抗人α干扰素抗体及其应用 | |
| JP2024544531A5 (https=) | ||
| TW202426471A (zh) | Il10突變體、融合蛋白和藥物 | |
| CN119546633A (zh) | 多特异性抗体及其用途 | |
| WO2023137143A1 (en) | Methods of contaminant removal from protein isolates | |
| CN116348481A (zh) | 使用工程化配体的材料和方法 |